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Prostate cancer incidence and mortality rates vary widely
among populations, with the highest documented rates
among American and Caribbean men of African descent
and the lowest rates in Asian populations. It is likely that
these diﬀerences can be attributed to variation in genetics,
environmental exposures, access to health care, screening
patterns, and treatment patterns; however, the reasons for
these diﬀerences have not been fully elucidated.
This special issue includes eight original research articles
that provide details regarding racial diﬀerences in incidence
ratesandmortalityratesandpathologicalfeaturesandwhich
help us to achieve a better understanding of environmental
and clinical reasons for these disparities. Two of the articles
examine the validity of prognostic indicators and treatment
recommendations in populations external to those in which
nomograms and treatment protocols were developed.
The ﬁrst research article, “Prostate cancer incidence rates
in Africa,” characterizes incidence rates within Sub-Saharan
Africa populations. Despite diﬀerences in data availability
and quality across the various locations included, the
authors provide strong evidence that incidence rates vary
considerably within Africa and that incidence rates are
rising in several Sub-Saharan Africa countries. The reported
incidence rates in Africa are much lower than those among
African American men but are similar to incidence rates of
distant-stage prostate cancer in African American men.
The next two articles address issues in prostate cancer
rates in Caribbean nations. A. J. M. Hennis et al. describe
prostate cancer incidence and mortality rates in Barbados
and compare these with rates among several other popula-
tions in “Prostate cancer incidence and mortality in Barbados,
West Indies.” In general, rates in Barbados do not diﬀer
from rates in other Carribbean populations and are lower
than those reported in African Americans. In “Environment
as a potential key determinant of the continued increase of
prostate cancer incidence in Martinique,” D. Belpomme and
P. Irigaray identiﬁed higher prostate cancer incidence rates
in Martinique compared with those in France, Sweden, the
USA,andtheUK.Reasonsforincidenceratediﬀerenceswere
examined using an ecological study approach, and evidence
favored genetic, pesticide exposure, or gene-environment
interaction explanations for rate diﬀerences, with no evi-
dence observed for a role of life expectancy or diet on
diﬀerences in incidence rates.
Important pathological diﬀerences in disease charac-
teristics by race are described in the fourth paper, “A
retrospective study on pathologic features and racial disparities
in prostate cancer.” S. A. Bigler et al. report diﬀerences in
the prevalence of key histologic and clinical features between
African American and Caucasian men at times of biopsy,
diagnosis, and prostatectomy. These diﬀerences include
younger age, higher cancer detection rate, higher Gleason
score, more bilateral prostate involvement, larger prostate
size, and greater tumor volume among African American
men compared with Caucasian men. Diﬀerences in tumor
evolution described include increased risk of diagnosis of2 Prostate Cancer
prostate cancer associated with diagnosis of high-grade
prostatic intraepithelial neoplasia (HGPIN) or atypical small
acinar proliferation (ASAP) among African American men
and shorter time from noncancerous biopsy to diagnostic
biopsy among men with HGPIN, with ASAP, or of African
American race.
Intheﬁftharticle,“Themetabolicsyndromeandbiochem-
ical recurrence following radical prostatectomy”b yJ .M .P o s t
et al., hypertension was the most common metabolic feature
in both African American and Caucasian prostate cancer
cases, with a signiﬁcantly greater presence among African
American men with prostate cancer. Metabolic syndrome
was associated with a 50% increase in risk of biochemical
recurrence (BCR), and hypertension was associated with
a two-fold increase in risk of BCR among both African
Americans and Caucasians.
In the sixth article, “Prostate cancer severity associations
with neighborhood deprivation,” C. M. Ziegler-Johnson et
al. report associations between several measures of neigh-
borhood and increased prostate cancer severity in neigh-
borhoods in Southeastern Pennsylvania, with the greatest
evidence for association observed within African Americans.
In the seventh article, “Racial/ethnic patterns in prostate
cancer outcomes in an active surveillance cohort,” J. Cullen
et al. compare secondary treatment and overall survival by
r a c e / e t h n i c i t yi nac o h o r to fm e nf o l l o w e do na na c t i v e
surveillance protocol. While black patients were more likely
to undergo secondary treatment, no racial diﬀerences in
overall survival were detected. Given current concerns in
the ﬁeld regarding the overtreatment of prostate cancer and
whether active surveillance is appropriate in black men,
these ﬁndings provide reassuring evidence that, at least
when secondary treatment availability is equal, there are no
diﬀerences in overall survival by race.
In the eighth article, “Development and external valida-
tion of a nomogram predicting the probability of signiﬁcant
GleasonsumupgradingamongJapanesepatientswithlocalized
prostate cancer,” T. Imamoto et al. describe a nomogram for
predicting Gleason sum upgrading from biopsy to radical
prostatectomy with better validity in Japanese men than
a previous nomogram developed in a Western popula-
tion. Given that approximately one-ﬁfth of Japanese men
diagnosed with prostate cancer at biopsy will experience
Gleason sum upgrade, this nomogram may aid clinicians in
identifying patients at higher risk of upgrade.
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